Schedule M area requirements: the short answer
Schedule M area requirements are set per dosage form, not per plant: a minimum manufacturing area and a separate minimum ancillary area for each category of manufacture. The most-quoted figures are 60 m² + 20 m² for an uncoated tablet section, 25 m² + 10 m² for hard-gelatin capsules, 30 m² + 10 m² for oral liquids and external preparations, and 150 m² + 100 m² for small-volume injectables.
Two things matter more than the numbers themselves. First, these are floors for one production section, not a plant footprint — warehouse, QC laboratory, change rooms and utilities sit outside them. Second, Revised Schedule M, notified as G.S.R. 922(E) on 28 December 2023[1], made the qualitative premises requirements the binding constraint: an area can meet the square-metre floor and still fail an inspection on flow, segregation and pressure cascade.
- 60 + 20m² — uncoated tablet section
- 150 + 100m² — small volume injectables
- 250 + 150m² — plastic LVP, form-fill-seal
- 1 Jan 2026MSME compliance deadline, now expired
Where the square-metre figures actually sit
This is the point most articles get wrong, and it changes how you use the table below.
Revised Schedule M is built around Part I — Good Manufacturing Practices for Pharmaceutical Products, whose section 12 (Premises) is written in WHO-GMP language and contains no square-metre figures at all. It requires, for example, that working and in-process storage space permit the orderly and logical positioning of equipment and materials so as to minimise the risk of confusion[2]. That is a design test, not an arithmetic one.
The dosage-form area figures live in the separate plant-and-equipment requirements annexed to Schedule M — the schedule of layout, area and recommended equipment for each category of manufacture. Those figures were carried across from the pre-2023 Schedule M essentially unchanged. So the numbers you were designing to in 2019 are still the numbers, while everything around them was rewritten.
Verification note. The area figures reproduced below are consistent across independent published reproductions of Schedule M, including one compiled directly from G.S.R. 922(E). The full notified gazette runs to well over a hundred pages and the dosage-form schedule sits deep inside it, so before you commit capital or file a licence application, read the figure for your category off the gazette itself[1] or have your State Licensing Authority confirm it in writing. Do not design a facility off any blog table, including this one.
Which area rule applies to your section
1. What are you manufacturing?
2. What class of molecule?
Pick a dosage form and a molecule class
The selector returns the minimum area that applies to that section, and the requirement that usually decides the inspection outcome.
Governing control point: awaiting selection
Schedule M area requirements by dosage form
Basic installation area is the production space itself. Ancillary area covers the directly attached support rooms — change rooms, air locks, washing and storage of in-process containers. Categories shown without an ancillary figure are stated in Schedule M with a basic-installation minimum only.
| Category of manufacture | Basic installation | Ancillary area | Approx. total |
|---|---|---|---|
| External preparations (ointments, creams, lotions) | 30 m² | 10 m² | 40 m² / 431 ft² |
| Oral liquid preparations | 30 m² | 10 m² | 40 m² / 431 ft² |
| Tablets — uncoated, non beta-lactam | 60 m² | 20 m² | 80 m² / 861 ft² |
| Tablets — coating section (additional) | 30 m² | 10 m² | 40 m² / 431 ft² |
| Tablets — uncoated, beta-lactam (separate section) | 60 m² | 20 m² | 80 m² / 861 ft² |
| Tablets — beta-lactam coating section (additional) | 30 m² | 10 m² | 40 m² / 431 ft² |
| Capsules — hard gelatin, non beta-lactam | 25 m² | 10 m² | 35 m² / 377 ft² |
| Capsules — hard gelatin, beta-lactam (separate section) | 25 m² | 10 m² | 35 m² / 377 ft² |
| Powders (oral) | 30 m² | not stated | 30 m² / 323 ft² |
| Ophthalmic preparations | 25 m² | 10 m² | 35 m² / 377 ft² |
| Surgical dressings | 30 m² | not stated | 30 m² / 323 ft² |
| Pessaries and suppositories | 20 m² | not stated | 20 m² / 215 ft² |
| Inhalers and vitrellae | 20 m² | not stated | 20 m² / 215 ft² |
| Repacking of drugs and pharmaceutical chemicals | 30 m² | not stated | 30 m² / 323 ft² |
| Parenterals — small volume injectables | 150 m² | 100 m² | 250 m² / 2,691 ft² |
| Parenterals — large volume | 150 m² | 150 m² | 300 m² / 3,229 ft² |
| Large volume parenterals in plastic, form-fill-seal | 250 m² | 150 m² | 400 m² / 4,306 ft² |
Scroll the table sideways on a phone. Conversions at 1 m² = 10.764 ft², rounded. Sourced from the plant-and-equipment schedule to Schedule M[1] — read the verification note above before designing to these figures.
A correction worth making. A widely repeated figure puts a tablet section at 30 m². That is the additional area for a coating section. An uncoated tablet section is 60 m² basic plus 20 m² ancillary; add the 30 + 10 coating block on top if you coat. Designing a tablet unit to 30 m² is a licence-application rejection waiting to happen.
What the table does not cover
Everything outside the production section
The minimum-area figures describe one manufacturing section and its directly attached ancillary rooms. A licensable unit also needs, at minimum:
- Warehouse — separate, demarcated areas for quarantine, approved, rejected, recalled and returned materials, plus controlled-temperature and, where applicable, narcotics storage.
- Quality control laboratory — physically separated from production, with its own instrument room, and a separate microbiology suite for sterile products.
- Change rooms and air locks — a personnel and a material air lock for each classified area; for sterile suites this is a multi-stage cascade, not a single room.
- Utilities — HVAC plant, purified water or water-for-injection generation and loop, compressed air, boiler and DG set, usually in a technical zone or on a service floor.
- Documentation, sampling, dispensing and washing rooms, and welfare areas kept out of the manufacturing block.
In practice this is why a plant designed to the bare section minima ends up two to four times the tabulated area once it is buildable. If you are sizing capital rather than rooms, the investment bands for a pharma manufacturing plant in India are the more useful starting point.
Where extra area is not optional
Certain product classes cannot share a building envelope, air handling system or personnel flow with general production. The area figure stays the same; the facility count changes.
- Beta-lactams — penicillins and cephalosporins require dedicated and self-contained facilities with independent air handling. Separate area and equipment for mixing, granulation, drying, compression, coating and packing must be provided; a beta-lactam tablet line is a second 60 + 20 m² section, not a partitioned corner of the first.
- Sex hormones, steroids and cytotoxic substances — the area requirement mirrors the corresponding tablet or injectable section, but must sit in a dedicated facility with containment and negative-pressure control relative to adjacent areas.
- Biologicals and live vaccines — separate premises and dedicated equipment, with additional containment obligations.
- Non-pharmaceutical lines — cosmetics, nutraceuticals and veterinary products carry their own segregation expectations and cannot be assumed to share a drug licence footprint.
The requirements that actually fail inspections
Since Revised Schedule M, an inspector is far more likely to write an observation against a design principle than against a tape measure. The recurring ones:
- Unidirectional flow — personnel, material, in-process goods and waste must not cross. A compliant-sized room with one door serving all four flows fails.
- Pressure cascade and air classification — differential pressures across classified areas, qualified HVAC, and documented recovery times.
- Environment of the site itself — premises must sit in surroundings that, taken with the protective measures in place, present minimum risk of contaminating materials or products[2].
- Separation of rest and refreshment areas from manufacturing and control areas[2].
- Qualification and validation — the rooms have to be shown to work, with IQ, OQ and PQ records and a site master file.
Run your own layout against these before an inspector does. Our Schedule M readiness self-assessment scores a unit across the twelve areas inspectors focus on.
Where compliance stands in 2026
- 28 December 2023Revised Schedule M notified as G.S.R. 922(E), replacing the schedule in force since 2001 and aligning Indian GMP with WHO-GMP structure[1].
- 11 February 2025G.S.R. 127(E) grants manufacturers with turnover of Rs. 250 crore or less a conditional extension to 31 December 2025, on condition they file an upgradation plan in Form A with the Central Licence Approving Authority within three months[3][4]. Reporting at the time put the number of MSME units in scope at over 8,500[5].
- November 2025The Drugs Controller General of India directs State drug controllers to begin immediate inspection of sub-Rs. 250 crore units that did not apply for the extension, and to plan inspections of those that did, with compliance required by 1 January 2026[6].
- 1 January 2026 onwardThe extension window has closed. Inspections and enforcement are running against units of every size. Non-compliance is now a licence question, not a planning question.
What this means for an area decision today. Before 2026 the calculation was how little space you could get a licence with. It is now whether an existing block can be re-partitioned into compliant flow at all — and for a lot of older units the honest answer is that acquiring or renting a facility already built to Revised Schedule M is faster and cheaper than retrofitting one that was not.
Himachal, Baddi and the retrofit-or-acquire question
Baddi, Kala Amb, Paonta Sahib and Solan hold a large share of India’s formulation capacity, much of it built to the pre-2023 schedule with 3 m to 3.5 m floor-to-ceiling heights, single-corridor layouts and HVAC sized for the old classification tables. Those constraints are structural. Widening a corridor to create a separate material air lock is a civil job; raising a slab to fit a ducted terminal-filter plenum usually is not.
The three questions worth answering before you spend on drawings:
- Is the shell tall enough? Below roughly 3.5 m structural clear height, a classified area with a proper ceiling void and pressure cascade becomes difficult without losing usable room height.
- Can flows be separated without demolition? If personnel and material entry can only ever share one door, the layout is not fixable by partitioning.
- What is the delta to an already-compliant unit? Compare the retrofit estimate against the acquisition or rental cost of a unit built to the revised schedule — that comparison, not the square-metre table, is usually what decides.
We list operating units across Baddi and the wider Himachal Pradesh cluster, and run the due diligence on layout, licence scope and Schedule M gap before a buyer commits.
Frequently asked questions
Schedule M does not set a single plant-level minimum. It sets a minimum basic installation area and a minimum ancillary area for each category of manufacture, and you add together the sections you intend to licence. An uncoated tablet section is 60 square metres basic plus 20 square metres ancillary; oral liquids and external preparations are 30 plus 10; small volume injectables are 150 plus 100. Warehouse, quality control laboratory, change rooms and utilities are additional and are not included in those figures.
A minimum of 60 square metres for the basic installation and 20 square metres of ancillary area for an uncoated tablet section. A coating section adds a further 30 square metres basic and 10 square metres ancillary. A beta-lactam tablet line does not share this space: it requires its own separate section of the same size with independent air handling. The frequently quoted figure of 30 square metres for tablets is the coating-section allowance being mistaken for the whole section.
Ancillary area is the support space attached directly to a production section, as distinct from the basic installation area where manufacturing actually happens. It covers change rooms, air locks, washing and cleaning rooms, storage of in-process containers and equipment, and the immediate documentation space. It does not extend to the central warehouse, the quality control laboratory or the utility block, which sit outside the section entirely and are sized on their own requirements.
The dosage-form area figures were carried across into the revised schedule substantially unchanged. What changed is everything around them. Part I of Revised Schedule M rewrote the general good manufacturing practice requirements along WHO-GMP lines, adding a pharmaceutical quality system, quality risk management, product quality review, computerised system controls and formal change control. In practice a facility now fails on flow, segregation, air classification and documentation far more often than on floor area.
Schedule M regulates built manufacturing area, not plot size, so there is no land figure in the rules. Working backwards from the section minima is the usual approach: total the sections you intend to licence, then allow for warehouse, quality control laboratory, utilities, change rooms and circulation, which together typically take two to four times the tabulated section area. Add setbacks, parking, effluent treatment and any expansion you want to keep open, then check the plot against local industrial building bye-laws, which are set by the state and not by Schedule M.
No. Schedule M to the Drugs Rules, 1945 sets good manufacturing practices and the requirements for premises, plant and equipment. It contains no list of medicines. The schedules that classify drugs by how they may be sold are different ones: Schedule H and H1 cover prescription-only medicines, and Schedule X covers drugs with additional record-keeping and storage controls. If you arrived here looking for a drug list, those are the schedules you want, not this one.
Get your layout checked against Revised Schedule M
Send us the floor plan and the licence scope you are applying for. We will mark up where the area, flow and segregation requirements are not met, and tell you plainly whether the block is worth retrofitting.
References
- Ministry of Health and Family Welfare, Government of India. G.S.R. 922(E): Notification of Schedule M, Drugs Rules, 1945. New Delhi: Gazette of India; 28 December 2023. Available from: https://cdsco.gov.in/opencms/opencms/system/modules/CDSCO.WEB/elements/download_file_division.jsp?num_id=MTA4MTU%3D. Accessed September 2026.
- Ministry of Health and Family Welfare, Government of India. Schedule M, Part I: Good Manufacturing Practices for Pharmaceutical Products, section 12 (Premises), as notified by G.S.R. 922(E). 28 December 2023.
- Ministry of Health and Family Welfare, Government of India. G.S.R. 127(E): Drugs (Amendment) Rules, 2025. New Delhi: Gazette of India; 11 February 2025. Available from: https://cdsco.gov.in/opencms/resources/UploadCDSCOWeb/2018/UploadGazette_NotificationsFiles/2025.02.11_G.S.R.%20127(E).pdf. Accessed September 2026.
- Press Information Bureau, Government of India. Conditional extension of timeline to small and medium pharmaceutical manufacturers for compliance with revised Schedule M notification. 2025. Available from: https://www.pib.gov.in/PressReleaseIframePage.aspx?PRID=2102291. Accessed September 2026.
- Business Standard. Over 8.5K MSME pharma units get 1-yr breather to adopt Schedule M standards. 12 February 2025. Available from: https://www.business-standard.com/health/small-pharma-companies-get-1-year-breather-to-implement-schedule-m-125021201111_1.html. Accessed September 2026.
- Pharmabiz. Revised Schedule M: CDSCO asks State regulators to take action on non compliant SMEs. 8 November 2025. Available from: https://www.pharmabiz.com/NewsDetails.aspx?aid=182319&sid=2. Accessed September 2026.
This page is technical and educational content for pharmaceutical professionals. It is not legal, regulatory or investment advice. Indian statutory instruments and their implementation timelines change frequently, and State Licensing Authorities apply them with local variation. Verify every figure against the notified gazette and your State Licensing Authority before acting on it.
